Introduction {#s1}
============

Multiple sclerosis (MS) is a potentially disabling central nervous system (CNS) disease characterized by inflammation, demyelination, and axonal degeneration. The pathophysiological mechanisms involved in this autoimmune disease differ between patients. In MS pathogenesis, antigen-presenting cells (APCs) stimulate CD4+ T cells in the periphery, favoring their differentiation into CD4+ T helper (Th) cells. Upon their activation, these immune cells cross the blood--brain barrier (BBB) and migrate into the brain, where they are reactivated by resident APCs. Proinflammatory cytokines and chemokines are released by reactivated CD4+ T cells, while infiltrated cytotoxic CD8+ T cells impair neuronal integrity. In parallel, plasma B cells release antibodies against self myelin epitopes, contributing to demyelination ([@B9]) ([**Figure S1**](#SM1){ref-type="supplementary-material"}).

An individual's genetic background and exposure to environmental factors confer risk of developing MS through epigenetic modifications ([**Figure 1**](#f1){ref-type="fig"}). DNA methylation (DNAme) is the most common epigenetic mechanism in somatic cells. This process occurs mainly in regulatory and promoter regions, where cytosine-guanine dinucleotides are markedly present ([@B43]). Although the precise mechanism of action of DNAme in MS remains to be fully elucidated, several studies have reported differentially methylated regions in either lymphocytes or peripheral blood mononuclear cells (PBMCs) and in *post-mortem* brain tissue ([**Table S1**](#SM1){ref-type="supplementary-material"}).

![Epigenetic modifications. These mechanisms are crucial for regulating gene transcription and chromatin architecture. Among them, we can highlight histone modifications, DNA methylation, and microRNAs. Covalent modifications of histones include acetylation, phosphorylation, sumoylation, ubiquitination, and methylation. DNA methylation is the most common epigenetic mechanism that occurs mainly in enriched CG dinucleotides regions in somatic cells. miRNAs are small non-coding RNA molecules that participate in RNA silencing. DNAme, DNA methylation; miRNA, microRNA; Me, methylation; Ub, ubiquitination; Ac, acetylation; P, phosphorylation.](fgene-10-01138-g001){#f1}

In this study, sets of differentially methylated genes described in the relevant literature are compared using Venn diagrams in order to determine the common, overlapping genes ([**Table 1**](#T1){ref-type="table"}). Although the studies included in this review have used a variety of methods, target samples, and subjects at different stages of the disease with distinct demographic characteristics that may contribute to DNAme heterogeneity, we assume that the common results reported at cell type level by different case studies could potentially explain in part MS pathophysiology. These results are summarized below.

###### 

Overlapped genes obtained after Venn diagram analysis.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene symbol   Reference   Methylation status   Comparison                                 Target sample                    Biological function
  ------------- ----------- -------------------- ------------------------------------------ -------------------------------- ---------------------------------------------------------------------------------------------------------
  **AHRR**      [@B5]       Hypo                 Within MS patients                         NAWM; demyelinated hippocampus   Homeostasis of the immune system

                [@B12]      Hypo                 RRMS *vs.* CTR                             CD4+ T cells                     

                [@B28]      Hypo                 Smoker MS *vs.* non-smoker MS              PMBCs                            

  **RASA3**     [@B5]       Hypo                 Within MS patients                         NAWM; demyelinated hippocampus   Inhibition of pathogenic Th17 cells

                [@B17]      Hyper                MS *vs.* CTR                               NAWM                             

                [@B21]      Hyper                RRMS *vs.* SPMS                            PMBCs                            

  **MORN1**     [@B12]      Hyper                RRMS *vs.* CTR                             CD4+ T cells                     Regulation of calcium homeostasis

                [@B27]      Hyper                MS *vs.* CTR                               CD8+ T cells                     

  **KIF25**     [@B5]       Hypo                 Within MS patients                         NAWM; demyelinated hippocampus   Motor protein involved in trafficking of vesicles, organelles, and proteins through the cytoskeleton

                [@B12]      Hypo                 RRMS *vs.* CTR                             CD4+ T cells                     

  **TGFBI**     [@B5]       Hypo                 Within MS patients                         NAWM; demyelinated hippocampus   Participate in calcium signaling and inflammation process

                [@B12]      Hyper                RRMS *vs.* CTR                             CD4+ T cells                     

  **USP35**     [@B12]      Hypo                 RRMS *vs.* CTR                             CD4+ T cells                     Deubiquitinating enzyme involved in type I interferon signaling

                [@B21]      Hyper                RRMS *vs.* SPMS                            PMBCs                            

  **MICB**      [@B12]      Hypo                 RRMS *vs.* CTR                             CD4+ T cells                     Involved in innate immune system regulation

                [@B17]      Hypo                 MS *vs.* CTR                               NAWM                             

  **IGSF9B**    [@B5]       Hyper                Within MS patients                         NAWM; demyelinated hippocampus   Cell adhesion molecule involved in GABAergic circuits

                [@B21]      Hyper                PPMS *vs.* CTR                             PMBCs                            

  **PSD3**      [@B4]       Hypo                 RRMS *vs.* CTR                             CD8+ T cells                     Control of neurite formation, spine density, trafficking of synaptic vesicles

                [@B5]       Hypo                 Within MS patients                         NAWM; demyelinated hippocampus   

  **HLA-F**     [@B17]      Hypo                 MS *vs.* CTR                               NAWM                             Regulation of immune response through antigen-processing mechanism

                [@B21]      Hypo                 PPMS *vs.* CTR                             PMBCs                            

  **GNAS**      [@B17]      Hypo                 MS *vs.* CTR                               NAWM                             Involved in Th17 activation and autoimmunity

                [@B21]      Hypo                 RRMS *vs.* CTR                             PMBCs                            

  **ATP11A**    [@B17]      Hyper                MS *vs.* CTR                               NAWM                             Possess an anti-inflammatory activity through internalization of macrophage TLR-4

                [@B21]      Hypo                 RRMS *vs.* CTR                             PMBCs                            

  **HOXC4**     [@B17]      Hypo                 MS *vs.* CTR                               NAWM                             Involved in vasculature pathways, nucleosome organization, and autoimmune disorders

                [@B21]      Hypo                 RRMS *vs.* CTR                             PMBCs                            

  **RARA**      [@B17]      Hypo                 MS *vs.* CTR                               NAWM                             Regulation of development, differentiation, apoptosis, granulopoiesis, and transcription of clock genes

                [@B28]      Hypo                 Smoker MS *vs.* non-smoker MS              PMBCs                            

  **PTPRN2**    [@B4]       Hypo                 RRMS *vs.* CTR                             CD8+ T cells                     Proliferation of regulatory T cells

                [@B17]      Hyper                MS *vs.* CTR                               NAWM                             

  **CDH1**      [@B17]      Hyper                MS *vs.* CTR                               NAWM                             Cell adhesion protein involved in synaptogenesis

                [@B24]      Hyper                RRMS (r) *vs.* CTR\                        cfpDNA                           
                                                 RRMS (r) *vs.* RRMS (e)                                                     

  **LINE-1**    [@B6]       Hyper                RRMS *vs.* CTR                             cfDNA (serum)                    Retrotransposons

                [@B35]      Hyper                MS naïve *vs.* MS IFN-β 1 year *vs.* CTR   PMBCs                            

  **RUNX3**     [@B17]      Hypo                 MS *vs.* CTR                               NAWM                             Coordination of DC, T, and NK cell differentiation

                [@B37]      Hyper                RRMS (e), RRMS (r) *vs.* CTR               Whole blood                      

  **CDKN2A**    [@B24]      Hyper                RRMS (r) *vs.* CTR                         cfpDNA                           Regulation of cell cycle

                [@B37]      Hyper                RRMS (e), RRMS (r)\                        Whole blood                      
                                                 *vs.* CTR                                                                   

  **SOCS1**     [@B24]      Hyper                RRMS (r) *vs.* CTR                         cfpDNA                           Regulation of proinflammatory cytokines release

                [@B37]      Hyper                RRMS (e) RRMS (r)\                         Whole blood                      
                                                 *vs.* CTR                                                                   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NAWM, normal appearing white matter; PBMCs, peripheral blood mononuclear cells; cfpDNA, cell-free plasma DNA; cfDNA, circulating free DNA.

The Immune System {#s1_1}
-----------------

The homeostasis of the immune system is modulated by the aryl hydrocarbon receptor (AHR). AHR activity is negatively regulated by the encoded protein for the aryl hydrocarbon receptor repressor (AHRR). MS patients showed lower expression levels of circulating AHR than their matched controls ([@B31]). In line with these findings, lower DNAme levels for AHRR have been measured in demyelinated hippocampi ([@B5]), CD4+ T cells ([@B12]), and PBMCs ([@B28]) of MS patients. This suggests that immune differentiation as well as the clinical course are compromised in MS ([@B31]). Furthermore, it is widely accepted that the major histocompatibility complex (MHC) plays a key role in the genetic susceptibility to MS. Two polymorphic genes, termed MHC class I chain-related gene A (MICA) and MHC class I chain-related gene B (MICB), are located within the MHC class I region. These molecules interact with specific receptors constitutively expressed in natural killer (NK) and T cells. The expression of MICB proteins in circulating PBMCs stimulates autoreactive T cells and favors MS progression ([@B1]). Similarly, [@B7] found that the MICB\*004 allele was significantly higher in MS patients than their matched controls. MS patients displayed lower DNAme levels for MICB compared to controls ([@B12]; [@B17]), in agreement with [@B1] and [@B7]. Runt-related transcription factor 3 (RUNX3) is expressed in dendritic cells (DCs), as well as T and NK cells, regulating their differentiation. In contrast, cyclin-dependent kinase inhibitor 2A (CDKN2A) controls the cell cycle, and it is abundantly expressed in oligodendrocytes and CD4+ and CD8+ T cells. In PBMCs collected from MS patients, both genes were underexpressed, which indicates a misbalance in CD4/CD8 T cell differentiation ([@B34]). In line with these findings, elevated levels of DNAme for RUNX3 and CDKN2A were found in MS patients compared to controls ([@B24]; [@B37]).

Innate Immune Response {#s1_2}
----------------------

In DCs, high levels of cyclic adenosine monophosphate (cAMP) activate Th17 response through the stimulation of guanine nucleotide-binding protein, alpha stimulating (GNAS). High levels of activated Th17 cells are associated with autoimmunity ([@B22]). In line with these findings, other studies have revealed a lower number of DNAme groups to GNAS ([@B17]; [@B21]) and consequently, an overactivation of Th17 cells. It is well-known that the recognition of CNS self-epitopes by monocytes facilitates type I interferon (IFN) release and thus, autoimmunity. IFN signaling is regulated by ubiquitination mechanisms. Ubiquitin-specific peptidase 35 (USP35), a member of the deubiquitinating enzyme family, reverses the process of ubiquitination and confers neuroprotection. During an inflammatory response, USP35 is underexpressed in monocytes. The expression of this deubiquitinating enzyme is higher when the inflammation is mitigated ([@B25]). Thus, we can speculate that a high number of DNAme groups to USP35 might occur in parallel with a relapsing MS course ([@B21]), while a hypomethylated pattern could favor a remitting course for the disease ([@B12]). In macrophages, the group of phosphatidylserines, a canonical substrate for ATPase phospholipid transporting 11A (ATP11A), is charged negatively and participates in the internalization of toll-like receptor 4 (TLR4). The internalization of TLR4 is essential to restricting long-term inflammatory responses. Deletion of ATP11A in humans causes an exacerbated inflammatory response ([@B42]). The addition of DNAme groups to ATP11A, which [@B17] described in the CNS of MS patients, might result in lower protein content and, consequently, chronic inflammation. However, [@B21] found an opposite effect, indicating that the expression of ATP11A was presumably higher in MS patients than controls. This discrepancy might suggest that the study of DNAme derived from PBMCs ([@B21]) was conducted during the remitting course of MS, when no signs of inflammation were present.

Adaptive Immune Response {#s1_3}
------------------------

CD4+ T cells proliferate into effector T cells in order to provide the most effective response to maintain immune homeostasis. Among CD4+ T cells, the Th17 subset regulates the immune response against autoimmunity. The generation of pathogenic Th17 (pTh17) cells is associated with an upregulation of RAS p21 protein activator 3 (RASA3). In contrast, reduced expression of RASA3 suppresses pTh17 cell generation *via* enhanced interleukin 4 synthesis ([@B45]). An elevated number of methyl groups for RASA3 was measured in normal-appearing white matter (NAWM) ([@B17]) and PBMCs ([@B21]), presumably due to the fact that MS patients displayed no radiological disease activity and absence of pTh17 cells. In contrast, [@B5] demonstrated a hypomethylated RASA3 pattern in the hippocampus during ongoing demyelination. Therefore, the migration of pathogenic lymphocytes into the MS brain originates in the destruction of myelin sheath and axonal degeneration through elevated levels of RASA3 ([@B45]). The activation of homeobox C4 (HOXC4) promotes the proliferation and differentiation of B cells ([@B33]). High mRNA transcription rates for HOXC4 are associated with dysfunctions in vasculature pathways and nucleosome organization ([@B29]) and have also been observed in autoimmune disorders ([@B33]). A lower number of methylated groups to HOXC4 would result in elevated protein levels, contributing to autoimmunity ([@B17]; [@B21]). The proliferation of regulatory T cells is achieved through the interaction of protein tyrosine phosphatase receptor type N2 (PTPRN2) with SMAD family member 3 (SMAD3) ([@B23]). A hypomethylated pattern of PTPRN2 has been described in T cells collected from MS patients ([@B4]). Thus, high levels of PTPRN2 might potentiate the proliferation of regulatory T cells. Interestingly, transforming growth factor, beta-induced (TGFBI) prevents autoimmunity by promoting T cell activation through Ca^2+^-calcineurin signaling ([@B11]). The addition of methyl groups to TGFBI in CD4+ T cells derived from MS patients ([@B12]) might prevent autoimmune reactivity favoring Ca^2+^-calcineurin signaling and T cell activation ([@B11]). Cytokines participate in the differentiation, maturation, and survival of immune cells. Suppressor of cytokine signaling 1 (SOCS1) regulates specifically the release of proinflammatory cytokines in MS. Under pathophysiological conditions, a significant reduction of SOCS1 has been measured in parallel with the synthesis of proinflammatory cytokines in MS ([@B40]). In agreement with [@B40], a substantial number of DNAme groups to SOCS1 might result in an acute inflammatory response, as has been reported in the context of MS ([@B24]; [@B37]).

Deoxyribonucleic Acid Damage {#s1_4}
----------------------------

The endoplasmic reticulum (ER), along with the plasma membrane (PM) junctions, is essential for Ca^2+^ homeostasis. ER Ca^2+^ depletion potentiates the inflammatory response, ER stress and, lastly, DNA damage ([@B44]). Upon activation of T-cell receptors (TCRs), protein junctions containing membrane occupation and recognition nexus (MORN) motifs stimulate a Ca^2+^ influx in T cells. Deficiency of protein junctions containing MORN motifs aggravates the store-operated Ca^2+^ entry in T cells and causes DNA damage ([@B44]). An elevated number of DNAme groups to MORN repeat containing 1 (MORN1) has been reported in both CD4+ and CD8+ T cells collected from MS patients ([@B12]; [@B27]) and might affect T cell viability ([@B44]). On the other hand, pleckstrin and Sec7 domain-containing 3 (PSD3) are predominantly expressed in the CNS ([@B36]), as well as in T cells, macrophages, and neutrophils ([@B32]). The Sec7 domain of PSD3 protein is a guanine nucleotide exchange factor for small GTPases that contributes to neurite formation, spine density, trafficking of synaptic vesicles, and receptor internalization ([@B32]). High levels of PSD3 activate Fas-induced apoptosis, while its depletion disrupts cell shape and polarity ([@B32]). In MS, a hypomethylation of PSD3 has been reported in both CD8+ T cells ([@B4]) and demyelinated hippocampi ([@B5]). This might suggest that immune homeostasis is unbalanced under these conditions ([@B32]).

*De novo* telomere addition of long interspersed nuclear elements (LINE-1) into genomic DNA causes genetic defects, alters the regulatory mechanisms and the structural properties of the genome at their insertion place and might lead to genomic remodeling ([@B8]). Changes in LINE-1 methylation status have been described in MS patients. Indeed, LINE-1 CpG sites were more frequently methylated in MS patients than in controls ([@B35]; [@B6]). A hypermethylated DNA pattern for LINE-1 in MS might be related to chromosomal abnormalities and DNA damage ([@B35]).

The Central Nervous System {#s1_5}
--------------------------

Observations of human MS plaques have revealed an increase of protein tyrosine phosphatases (PTPs) during ongoing remyelination ([@B15]). In NAWM derived from MS patients, the addition of DNAme to PTPRN2 ([@B17]), a member of the PTP family, indicates that the CNS integrity remains unaltered. An upregulation of TGFBI is involved in CNS repair after brain injury through the inhibition of the inflammatory response, mediated by activated microglia. Therefore, TGFBI acts as a suppressor of microgliosis ([@B19]). Consequently, lower DNAme levels to TGFBI in the demyelinated hippocampus of MS patients might occur in order to counteract the deleterious effect associated with the activation of microglia ([@B19]). Kinesins (KIFs), a family of motor proteins mainly expressed in neurons, immune cells, and oligodendrocytes, are involved in the trafficking of vesicles, organelles, and proteins through the cytoskeleton ([@B16]). An overexpression of KIF improves axonal transport, while its downregulation leads to neurodegeneration and CNS atrophy ([@B26]). Dysregulation of certain KIFs has been postulated to aggravate MS disease ([@B14]). Lower methylated levels for KIF family member 25 (KIF25) have been measured in the hippocampi ([@B5]) and CD4+ T cells ([@B12]) of MS patients. Thus, it is plausible that lower DNAme levels could increase the production of KIF motor proteins to compensate the increased CNS molecule transport demand in MS patients. Cell adhesion molecules (CAMs) participate in axon guidance, synaptogenesis, and neuronal regeneration ([@B13]). Immunoglobulin superfamily member 9B (IGSF9B) is a member of the CAM family highly expressed in GABAergic interneurons, macrophages/microglia, and astrocytes ([@B10]). IGSF9B is also constitutively expressed in circulating monocytes ([@B41]); however, its biological function in this cell type remains unclear and thus requires further investigation. Elevated expression of IGSF9B favors the maintenance of inhibitory synapses ([@B10]), while low levels result in a selective loss of GABAergic interneurons ([@B30]). A prominent loss of GABAergic circuits has been described in MS ([@B10]). The findings reported by [@B5] and [@B21] suggest that a substantial number of DNAme to IGSF9B could be accompanied by lower transcription rates as well as a selective loss of GABAergic interneurons ([@B10]). In MS, HLA class I histocompatibility antigen, alpha chain F (HLA-F) cooperates with the antigen-processing peptide-loading complex, regulating the immune response *via* NK receptors ([@B2]). An overexpression of HLA-F protects neurons from astrocyte-mediated neurotoxicity ([@B38]). Thus, it can be hypothesized that a lower number of methyl groups to HLA-F might confer neuroprotection. In this regard, [@B17] found a hypomethylation of HLA-F promoter in NAWM collected from MS patients compared to their controls. It is noteworthy that RUNX3, a transcription factor importantly involved in DC and T and NK cell differentiation, is upregulated in active and chronic MS lesions ([@B37]). Similarly, [@B17] reported a hypomethylated DNA pattern for RUNX3 in NAWM collected from MS patients. This indicates that RUNX3 DNAme status could be used as an inflammatory biomarker even when inflammation is apparently not present in the CNS ([@B17]). When retinoic acid (RA) interacts with retinoic acid receptor alpha (RARA), several transcriptional changes affecting the immune system and CNS repair can take place. Indeed, the inflammatory activity observed in MS patients is attenuated upon stimulation of RARA ([@B20]). In line with these findings, [@B17] reported a hypomethylated DNAme pattern for RARA in MS NAWM, which suggests no inflammatory activity ([@B17]). Additionally, [@B28] found a smaller number of DNAme groups for RARA in tobacco smokers with MS compared to non-smokers diagnosed with MS, which is apparently related to tobacco consumption ([@B39]). Cadherins are widespread calcium-dependent cell adhesion proteins involved in cell-cell adhesion, mobility, and proliferation of epithelial cells. In particular, cadherin 1 (CDH1) participates in many aspects of synapse formation and function ([@B3]). Recently, [@B18] identified a large percentage of single nucleotide polymorphisms (SNPs) that may confer risk of MS. Among them, rs1886700 is statistically associated with lower expression of CDH1. Therefore, an increase of DNAme to CDH1 ([@B24]; [@B17]) probably leads to lower mRNA transcription rates and a worse disease course in MS ([@B18]).

Conclusions and Perspectives {#s2}
============================

Multiple sclerosis is a chronic inflammatory CNS disease originating from a complex interaction between genes and the environment. As far as we know, genetics accounts for almost 30% of MS prevalence worldwide, while the remaining percentage corresponds to epigenetic modifications due to exposure to distinct environmental factors ([@B43]). This review summarized the common differentially methylated genes expressed in distinct cell types and tissues derived from MS patients in order to elucidate their role in the pathophysiology of the disease. We conclude that changes in the methylation status of certain genes cause chromosomal abnormalities, DNA damage, and the generation of pathogenic immune cells resulting in inadequate innate and adaptive immune response. Furthermore, we assume that aberrant epigenetic profile in the context of disease potentiates microgliosis, alterations in synapse formation and function, and a selective loss of GABAergic interneurons which in turn favors neurodegeneration. A deeper understanding of the underlying physiological mechanisms mediated by DNAme will contribute to the development of new strategies in MS prognosis and therapy.
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